An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CSL Behring
Age
12–65
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of severe hemophilia A defined as \<1% FVIII:C documented in medical records.
Males between 18 and 65 years of age (Parts 1 and 2).
Males between 12 and 65 years of age (Part 3).
Subjects who have received or are currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have had \>150 exposure days (EDs) with a FVIII product
Written informed consent for study participation obtained before undergoing any study specific procedures.
You may not be if
Any history of or current FVIII inhibitors
Any first order family history of FVIII inhibitors
Use of an Investigational Medicinal Product within 30 days prior to the first rVIII-SingleChain administration.
Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain or reference product.
Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein.
Any known congenital or acquired coagulation disorder other than congenital FVIII deficiency.
Platelet count \< 100,000/µL at screening.
Human immunodeficiency virus (HIV) positive subjects with a CD4 count \< 200/mm3, in their medical history or at screening if available results are older than one year. (HIV positive subjects may participate in the study and antiviral therapy are permitted, at the discretion of the Investigator).
Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment.
Subject with serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) values \> 5 times (x) the upper limit of normal (ULN) at Screening.
Subjects with serum creatinine values \> 2 x ULN at Screening.
Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to Day 1.
Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to Day 1.
Clareo Health | An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
